|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Temporary amelioration of hyperlipidemia in low density lipoprotein receptor-deficient rabbits transplanted with genetically modified hepatocytes.
|
2236051 |
1990 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Although our recent data confirmed this high frequency of heterozygous FH in our pediatric population with hypercholesterolemia, none of the five established molecular defects for the French-Canadian population was detected in 29% of the unrelated French-Canadian children characterized by a persistent increase in LDL (low density lipoprotein receptor) cholesterol and a positive parental history of hyperlipidemia (Assouline et al., 1995).
|
9195230 |
1997 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
We tested the efficacy of adenovirus-mediated gene transfer of LPL as treatment of experimental hyperlipidemias associated with apolipoprotein (apoE) deficiency (apoE-/-) and low-density lipoprotein receptor (LDLr) deficiency (LDLr-/-) in mice.
|
9382958 |
1997 |
|
Hyperlipidemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Use of this marker in the families of twenty-three FH probands from Hampshire demonstrated co-segregation of the hyperlipidaemia phenotype with the LDLR gene region, except in one family with defective apolipoprotein B-100, and a family turning out to display familial combined hyperlipidaemia.
|
9543550 |
1997 |
|
Hyperlipidemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Cosegregation of E397X mutation and LDLR gene RFLP haplotypes with hyperlipidemia was demonstrated by family study.
|
9889019 |
1998 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor.
|
10024503 |
1999 |
|
Hyperlipidemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These observations testify to the biological complexity of genotype-environment interactions in individuals carrying mutations at the LDL-R locus and indicate that genetic analysis importantly complements the clinical and biochemical diagnosis of patients with hyperlipidemia.
|
10924730 |
2000 |
|
Hyperlipidemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Four other first-degree relatives had hyperlipidemia but no LDL-receptor mutation.
|
11238294 |
2001 |
|
Hyperlipidemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Only a single sequence variation, a missense mutation in the low density lipoprotein receptor gene, co-segregated with hyperlipidemia in the proband's family.
|
11381031 |
2001 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
CTD_human |
Low density lipoprotein receptor deficient (LDLR-KO) and apolipoprotein E deficient (apo E-KO) mice both develop hyperlipidemia and atherosclerosis by different mechanisms.
|
11947894 |
2002 |
|
Hyperlipidemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Molecular analysis of the LDL receptor gene will clearly identify the cause of the patient's hyperlipidemia and allow appropriate early treatment as well as antenatal and family studies.
|
12837857 |
2003 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recent studies on LDL receptor-deficient mice that are hyperglycemic, but exhibit no marked dyslipidemia compared with nondiabetic controls, show that diabetes in the absence of diabetes-induced hyperlipidemia is associated with an accelerated formation of atherosclerotic lesions, similar to what is seen in fat-fed nondiabetic mice.
|
17395883 |
2007 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Conversely, absence of SREBP-1 suppressed Western diet-induced hyperlipidemia in LDLR-deficient mice and ameliorated atherosclerosis.
|
21546605 |
2011 |
|
Hyperlipidemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In experimental animal models of FH, LDLr overexpression following viral vector-based gene transfer has been shown to be associated with long-term stable correction of hyperlipidemia, with attenuation of atherosclerosis progression, and in certain cases even with lesion regression.
|
21774774 |
2011 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Herein, in low-density lipoprotein receptor-deficient hyperlipidemic and streptozotozin-induced diabetic mice, hyperglycemia and hyperlipidemia acted reciprocally, accentuating renal injury and altering renal function.
|
23318573 |
2013 |
|
Hyperlipidemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Chow-fed hypomorphic Apoe mice deficient in low-density lipoprotein receptor expression (Apoe(h/h)Ldlr(-/-)Mx1-cre mice) develop hyperlipidemia and atherosclerosis.
|
23788760 |
2013 |
|
Hyperlipidemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Several novel therapies have been introduced for the treatment of people with genetic defects that result in loss of function within the LDL receptor, a major determinant of inherited hyperlipidaemias.
|
25131980 |
2014 |
|
Hyperlipidemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
BBR activates hepatic Raf-1 signaling and up-regulates LDL receptor expression in a rat model of hyperlipidemia with no impact on liver Ras activity.
|
25196457 |
2014 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Additionally, plasma lipid concentration lowering effects of PB-liposome/G5-PEG were evaluated in vivo in a LDLR-/- hyperlipidemia mouse model.
|
25587935 |
2015 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
CTD_human |
Bisphenol A exposure induces metabolic disorders and enhances atherosclerosis in hyperlipidemic rabbits.
|
25619500 |
2015 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The strongest associations for lipid levels change were detected at LPL, TRIB1, APOA1-C3-A4-A5, LIPC, CETP, and LDLR (P range from 4.84×10(-4) to 4.62×10(-18)), whereas LPL, TRIB1, ABCA1, APOA1-C3-A4-A5, CETP, and APOE displayed significant strongest associations for incident hyperlipidemia (P range from 1.20×10(-3) to 4.67×10(-16)).
|
26582766 |
2016 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
We describe two novel immunodeficient mouse models of hyperlipidemia (Rag1<sup>-/</sup><sup>-</sup>/LDLR<sup>-/</sup><sup>-</sup> and Rag1<sup>-/</sup><sup>-</sup>/ApoE (apolipoprotein E)<sup>-/</sup><sup>-</sup> mice) in addition to established immunocompetent LDLR<sup>-/</sup><sup>-</sup> and ApoE<sup>-/</sup><sup>-</sup> mice.
|
28759039 |
2017 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our findings demonstrate that the Ldlr KO hamster is an animal model of choice for human FH and has great potential in translational research of hyperlipidemia and coronary heart disease.
|
29289533 |
2018 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Hepatic NPC1L1 promotes hyperlipidemia in LDL receptor deficient mice.
|
29601818 |
2018 |